Results for the substance 20 valent adsorbed conjugated polysaccharide pneumococcal vaccine

The 20-valent adsorbed pneumococcal polysaccharide conjugate vaccine is designed to protect against infections caused by 20 different serotypes of the Streptococcus pneumoniae bacterium. It is used to prevent invasive pneumococcal diseases such as pneumonia, meningitis, and sepsis, as well as otitis media, particularly in high-risk groups such as young children, the elderly, and individuals with chronic conditions or immunosuppression.

This vaccine is a conjugate and adsorbed product, meaning that the capsular polysaccharides of the bacterium are linked to a carrier protein and fixed onto an adjuvant (usually aluminum hydroxide). This combination enhances the immune response, increasing the vaccine's effectiveness, especially in children under 2 years old and individuals with weakened immune systems.

The vaccine is administered via intramuscular injection according to a vaccination schedule established by public health authorities. It is well-tolerated, but mild side effects such as pain at the injection site, fever, fatigue, or irritability may occur. Severe reactions, such as allergic responses, are rare.

Following the recommended vaccination schedule is essential to ensure optimal protection against pneumococcal diseases.